Aaron Cowen Suvretta Capital Management
Aaron Cowen is the founder of Suvretta Capital Management, a long/short equity firm with a fundamental research process. The firm invests across sectors with an emphasis on differentiated fundamental views. Cowen’s disclosures are tracked by investors who follow mid-to-large fundamental hedge funds.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Coca-Cola
KO
|
+$32.8M |
| 2 |
Apple
AAPL
|
+$32.1M |
| 3 |
ArriVent BioPharma
AVBP
|
+$31.5M |
| 4 |
argenx
ARGX
|
+$26.4M |
| 5 |
CRH
CRH
|
+$25.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ACLX
Arcellx
ACLX
|
+$55.4M |
| 2 |
Royalty Pharma
RPRX
|
+$48.3M |
| 3 |
Las Vegas Sands
LVS
|
+$36.3M |
| 4 |
Microsoft
MSFT
|
+$33.4M |
| 5 |
TERN
Terns Pharmaceuticals
TERN
|
+$29.2M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.68% |
| 2 | Technology | 7.85% |
| 3 | Communication Services | 7.05% |
| 4 | Consumer Discretionary | 4.46% |
| 5 | Financials | 3.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Charles River Laboratories
CRL
$14.1B
| $274K | 0.01% |
1,010
| – | – |
|
102
Agios Pharmaceuticals
AGIO
$1.98B
| – | – |
-399,451
| Closed | -$8.9M |
|
103
AnaptysBio
ANAB
$1.71B
| – | – |
-354,872
| Closed | -$7.6M |
|
104
AstraZeneca
AZN
$257B
| – | – |
-35,245
| Closed | -$4.75M |
|
105
Idexx Laboratories
IDXX
$43.9B
| – | – |
-920
| Closed | -$511K |
|
106
Incyte
INCY
$25.9B
| – | – |
-37,600
| Closed | -$2.36M |
|
107
CALL
KraneShares CSI China Internet ETF
KWEB
$5.28B
| – | – |
-900,000
| Closed | -$24.3M |
|
|
108
Las Vegas Sands
LVS
$30.5B
| – | – |
-738,163
| Closed | -$36.3M |
|
109
Merck
MRK
$376B
| – | – |
-15,500
| Closed | -$1.69M |
|
110
Pfizer
PFE
$160B
| – | – |
-50,300
| Closed | -$1.45M |
|
111
Sana Biotechnology
SANA
$1.17B
| – | – |
-1,606,056
| Closed | -$6.55M |
|
112
Bio-Techne
TECH
$11.3B
| – | – |
-2,600
| Closed | -$201K |
|
113
United Therapeutics
UTHR
$22B
| – | – |
-1,360
| Closed | -$299K |
|
Similar funds
Aaron Cowen's Q1 2024 Portfolio in Review
As of Q1 2024, Aaron Cowen held 113 positions worth $2.69B, up 22% from $2.21B the previous quarter. Its ten largest holdings account for 44% of the portfolio.
Aaron Cowen deployed $129M of net new capital in Q1 2024, opening 25 new positions and adding to 16 existing holdings. Its largest new stake was Coca-Cola: 546,500 shares worth $33.4M.
By sector, the portfolio is most concentrated in Healthcare at 60% of assets, down from 70% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Arcellx, an estimated $55.4M trimmed.
- Aaron Cowen's largest Q1 2024 buy was Coca-Cola: 546,500 shares worth $33.4M.
- Aaron Cowen added most to argenx in Q1 2024, an estimated $26.4M increase.
- Aaron Cowen's biggest Q1 2024 reduction was Arcellx, cutting an estimated $55.4M.
- Aaron Cowen fully exited Las Vegas Sands in Q1 2024, selling an estimated $36.3M.
- Aaron Cowen's ten largest holdings make up 44% of its $2.69B portfolio in Q1 2024.
- Aaron Cowen opened 25 new positions and closed 12 in Q1 2024.
- Aaron Cowen's portfolio value rose 22% quarter-over-quarter to $2.69B.
Based on Suvretta Capital Management's 13F filing for Q1 2024, filed 15 May 2024.